MedTrace Logo

Effect of Restriction of Foods Containing Phosphorus Additives

NCT01965379 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2015-03-10

No results posted yet for this study

Summary

Hyperphosphatemia is related to the increase in morbidity and mortality. There is greater risk for cardiovascular disease, atherosclerotic disease, secondary hyperparathyroidism, and bone disease .

The serum phosphorus level can be controlled by a combination of factors, such as: reduction of ingestion, reduction of intestinal absorption with chelating agents and increase in elimination by dialysis.

The purpose of this study is to evaluate the effect of dietary intervention consisting of the restriction of industrialized foods with phosphorus additives in chronic kidney disease patients treated with hemodialysis.

Conditions

  • End-stage Renal Disease
  • Hyperphosphatemia

Interventions

OTHER

Restriction on food containing phosphorus additives

The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.

OTHER

Standard care

The control group mantained the usual renal diet oriented prior to the study with a booklet.

Sponsors & Collaborators

  • Faculdade de Ciências Médicas da Santa Casa de São Paulo

    lead OTHER

Principal Investigators

  • Yvoty AS Sens, PHD · Faculdade de Ciências Médicas da Santa Casa de São Paulo

  • Margareth LL Fornasari, RD · Faculdade de Ciências Médicas da Santa Casa de São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-12-31
Completion
2014-06-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01965379 on ClinicalTrials.gov